Skip to main content

Table 3 Diagnostic performance of the 25-Gene Panel urine test in a retrospective training cohort (n = 614), a prospective validation cohort (n = 396), a combination cohort (n = 1010), and cross-validation of the combination cohort (n = 1010)

From: Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up

  Retrospective cohort Prospective cohort Combination cohort Cross-validation
  Positive Negative Total Positive Negative Total Positive Negative Total Positive Negative Total
PCa 481 39 520 176 31 207 657 70 727 644 83 727
Non-PCa 8 86 94 10 179 189 18 265 283 27 256 283
Total 489 125 614 186 210 396 675 335 1010 671 339 1010
Sensitivity (95% CI) 92.5% (94.8–90.2%) 85.0% (89.9–80.2%) 90.4% (92.5–88.2%) 88.6% (90.9–86.3%)
Specificity (95% CI) 91.5% (97.1–85.9%) 94.7% (97.9–91.5%) 93.6% (96.5–90.8%) 90.5% (93.9–87.0%)
PPV (95% CI) 98.4% (99.5–97.2%) 94.6% (97.9–91.4%) 97.3% (98.6–96.1%) 96.0% (97.5–94.5%)
NPV (95% CI) 68.8% (76.9–60.7%) 85.2% (90.0–80.4%) 79.1% (83.5–74.8%) 75.5% (80.1–70.9%)
Odds ratio (95% CI) 132.6 (293.5–59.9) 101.6 (213.5–48.4) 138.2 (236.5–80.8) 73.6 (116.3–46.6)
  1. PPV positive predictive value, NPV negative predictive value, CI confidence interval
\